Los Angeles Capital Management
BIO icon

Los Angeles Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Los Angeles Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.7K Hold
74
– – ﹤0.01% 1759
2026
Q1 		$20.6K Sell
74
-79
-52% -$22.8K ﹤0.01% 1737
2025
Q4 		$46.6K Buy
+153
New +$47.7K ﹤0.01% 1619
2023
Q4 		– Sell
-3,667
Closed -$1.31M – 1137
2023
Q3 		$1.31M Sell
3,667
-10,614
-74% -$4.1M 0.01% 549
2023
Q2 		$5.41M Sell
14,281
-170,515
-92% -$69.4M 0.02% 326
2023
Q1 		$88.5M Buy
+184,796
New +$86.5M 0.39% 61
2022
Q2 		– Sell
-1,885
Closed -$1.06M – 1331
2022
Q1 		$1.06M Sell
1,885
-7,466
-80% -$4.5M ﹤0.01% 732
2021
Q4 		$7.07M Buy
9,351
+8,171
+692% +$6.11M 0.03% 307
2021
Q3 		$880K Buy
+1,180
New +$884K ﹤0.01% 807
2021
Q1 		– Sell
-860
Closed -$501K – 1582
2020
Q4 		$501K Sell
860
-40
-4% -$22.8K ﹤0.01% 1206
2020
Q3 		$464K Buy
900
+40
+5% +$20.3K ﹤0.01% 1110
2020
Q2 		$388K Sell
860
-880
-51% -$388K ﹤0.01% 1210
2020
Q1 		$610K Sell
1,740
-70
-4% -$25.7K ﹤0.01% 845
2019
Q4 		$670K Sell
1,810
-1,809
-50% -$638K ﹤0.01% 944
2019
Q3 		$1.2M Sell
3,619
-7,324
-67% -$2.39M 0.01% 760
2019
Q2 		$3.42M Buy
10,943
+1,190
+12% +$356K 0.02% 526
2019
Q1 		$2.98M Buy
9,753
+5,730
+142% +$1.55M 0.02% 542
2018
Q4 		$934K Sell
4,023
-3,485
-46% -$935K 0.01% 765
2018
Q3 		$2.35M Sell
7,508
-26,035
-78% -$8.08M 0.01% 627
2018
Q2 		$9.68M Sell
33,543
-2,550
-7% -$704K 0.05% 358
2018
Q1 		$9.03M Buy
36,093
+4,085
+13% +$1.04M 0.05% 333
2017
Q4 		$7.64M Sell
32,008
-410
-1% -$99.4K 0.04% 379
2017
Q3 		$7.2M Sell
32,418
-1,076
-3% -$242K 0.04% 370
2017
Q2 		$7.58M Buy
33,494
+11,635
+53% +$2.54M 0.05% 369
2017
Q1 		$4.36M Buy
+21,859
New +$4.21M 0.03% 433

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Los Angeles Capital Management's BIO Position: Q2 2026 in Review

Los Angeles Capital Management held its Bio-Rad Laboratories Class A (BIO) position steady in Q2 2026 at 74 shares worth $21.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1759.

Los Angeles Capital Management first reported a position in BIO in Q1 2017 and has held it in 25 quarters since. The position peaked at $88.5M in Q1 2023. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Los Angeles Capital Management held 74 shares of Bio-Rad Laboratories Class A worth $21.7K as of Q2 2026.
  • Los Angeles Capital Management left its Bio-Rad Laboratories Class A share count unchanged in Q2 2026.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1759 holding.
  • Los Angeles Capital Management first reported a position in Bio-Rad Laboratories Class A in Q1 2017 and has held it in 25 quarters since.
  • Los Angeles Capital Management's Bio-Rad Laboratories Class A position peaked at $88.5M in Q1 2023.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.